Mifepristone Manufacturers Urge Supreme Court to Stall New In-Person Dispensing Rule
The makers of the abortion pill mifepristone have launched an emergency appeal to the Supreme Court seeking an immediate pause on a ruling from the 5th US Circuit Court of Appeals that would reinstate nationwide in-person dispensing requirements for the drug. This fast-track petition thrusts the abortion pill back into the highest court’s spotlight less than two years after it upheld its broad availability.
Danco Laboratories, the manufacturer, argues the 5th Circuit’s decision “injects immediate confusion and upheaval into highly time-sensitive medical decisions” across states including New York, Minnesota, and Washington. The company warns that patients arriving for scheduled appointments risk being turned away, and questions how those unable to obtain prompt in-person visits will access the pill.
Ruling Threatens Telehealth Abortion Access as Medication Abortions Soar Nationwide
The emergency request follows the 5th Circuit’s recent reinstatement of a rule requiring patients to visit healthcare providers in person to receive mifepristone, one of the two medicines used in medication abortion. This change threatens to reverse progress made since the COVID-19 pandemic, when telehealth appointments enabled remote access to the drug under rules finalized by the Biden administration after the Supreme Court’s overturning of Roe v. Wade.
Medication abortions have surged, now accounting for more than 60% of all abortions in the US according to Guttmacher Institute data, as clinic access has tightened in conservative states. The reinstated requirement could force women in many areas to travel for appointments during narrow time windows, causing delays or blocked access.
The appeal requests that the Supreme Court impose an “administrative stay” to immediately suspend the 5th Circuit’s ruling and take the case for full consideration on the merits. The drug maker’s legal brief highlights the chaos caused when pharmacies and clinics suddenly must deny patients prescribed the drug under prior rules.
Legal Fight Highlights Broader Clash Over Abortion Access Post-Roe
The 5th Circuit ruling originated from a lawsuit filed by Louisiana, which claims the Biden-era FDA regulations on mifepristone undercut its abortion restrictions. A federal district court earlier declined to block access until a new FDA safety review was completed. Data reviewed by CNN confirms the drug’s safety profile is strong, with fewer side effects than many common medications like Viagra or penicillin.
The high court’s involvement signals a crucial test of abortion pill access nationwide, at a time when medication is the most widely used abortion method and political battles over reproductive rights intensify. This appeal, filed directly with Justice Samuel Alito, a conservative court member, comes as millions of women face uncertainty over how and where they can legally obtain abortion care.
What Happens Next?
The Supreme Court is expected to address the emergency request rapidly given the urgent nature of abortion access and the disruption the ruling is causing across the country. If the court pauses the 5th Circuit decision, telehealth access for mifepristone will remain intact for now. If not, the ruling could trigger a patchwork of restrictions, disproportionately affecting women in rural or conservative states—including many in Kentucky’s neighboring regions.
Kentucky residents and others watching nationwide will need to stay alert as this case develops, with immediate consequences for reproductive healthcare providers, patients, pharmacies, and the broader legal landscape surrounding abortion rights.
Kentucky Insider will provide updates as the Supreme Court takes up this pivotal case on medication abortion access.
